PO.BCS01.10 · 生物信息与计算
miRNA对前列腺癌中AR-PI3K/MAPK串扰及EMT的协调调控
Coordinated miRNA regulation of AR-PI3K/MAPK crosstalk and EMT in prostate cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
前列腺癌(PCa)的进展与治疗耐药关键依赖于雄激素受体(AR)轴及主要生存网络,包括PI3K/AKT、MAPK及上皮-间质转化(EMT)程序。虽然个别微小RNA(miRNA)已被认为参与这些通路,但控制这些相互关联的致癌轴的更广泛的miRNA驱动调控系统仍知之甚少。我们在一个临床注释完善的PCa队列中进行了miRNA表达谱分析,并开展整合分析,通过网络相关性、通路富集及映射至已确立的致癌与EMT相关特征评分来识别功能性miRNA簇。随后将基于文献的功能注释与我们的miRNA发现相结合,以研究与关键EMT转录因子及PTEN等肿瘤抑制因子的相关性。我们识别出不同的miRNA簇,其靶点共同汇聚于共同的致癌枢纽,包括AR-PI3K/MAPK-WNT/NOTCH信号。在EMT调节中发挥作用方面,若干miRNA与EMT转录因子表现出强烈负相关,包括miR-221-5p和miR-542-3p与SNAI2(r约-0.5),以及miR-378d和miR-449b-5p与ZEB2(r约-0.7和-0.4),支持它们在抑制EMT程序中的功能性参与。此外,miR-542-3p、miR-449b-5p和miR-302d-3p与PTEN呈负相关(-0.7、-0.5、-0.5),提示它们参与PI3K/AKT通路调节。这些发现与miR-206、miR-302d-3p和miR-2110已确立的肿瘤抑制作用一致——这些miRNA先前被关联至MAPK/ERK、AKT/mTOR及FGFR/RTK-PTEN调控轴(Cancers 2024)。通路富集分析揭示,被靶向的通路,包括WNT、NOTCH1、PI3K/AKT、MAPK、ERBB2及FGFR信号,构成一个相互关联的致癌网络。在此框架内,miR-378d和miR-449b-5p与ERBB2表现出强烈负相关(分别为-0.7和-0.5)。与这些分子相互作用一致,与Scote衍生的致癌特征(包括ERBB2激活与BRCAness)的相关性表明,miRNA簇与基因组不稳定性、增殖及治疗耐药表型强烈相关。总体而言,这些发现提示所识别的miRNA簇作为整合的调控模块发挥作用,同时协调对AR信号串扰的抑制与PI3K/MAPK激活及EMT的调节。它们与Scote致癌特征及EMT转录因子的强关联,突显了其作为预后生物标志物以及作为旨在破坏AR-生存网络串扰并克服治疗耐药的合理联合策略靶点的潜力。
查看英文原文 English abstract
Prostate cancer (PCa) progression and therapeutic resistance are critically dependent on the Androgen Receptor (AR) axis and major survival networks, including PI3K/AKT, MAPK, and epithelial-mesenchymal transition (EMT) programs. While individual microRNAs (miRNAs) have been implicated in these pathways, the broader miRNA-driven regulatory systems controlling these interconnected oncogenic axes remain poorly understood. We performed miRNA expression profiling in a clinically well-annotated PCa cohort and conducted an integrative analysis, identifying functional miRNA clusters through network correlation, pathway enrichment, and mapping to established oncogenic and EMT-related signature scores. Literature-based functional annotation was then combined with our miRNA findings to investigate correlations against key EMT transcription factors and tumour suppressors such as PTEN. We identified distinct miRNA clusters whose targets collectively converge on common oncogenic hubs, including AR-PI3K/MAPK-WNT/NOTCH signalling. With a role in EMT modulation, several miRNAs displayed strong negative correlations with EMT transcription factors, including miR-221-5p and miR-542-3p with SNAI2 (r ~ -0.5), and miR-378d and miR-449b-5p with ZEB2 (r ~ -0.7 and -0.4), supporting their functional involvement in suppressing EMT programs. Additionally, miR-542-3p, miR-449b-5p, and miR-302d-3p correlated inversely with PTEN (-0.7, -0.5, -0.5), suggesting their participation in PI3K/AKT pathway modulation. These findings align with the established tumour-suppressive roles of miR-206, miR-302d-3p, and miR-2110-previously linked to MAPK/ERK, AKT/mTOR, and FGFR/RTK-PTEN regulatory axes (Cancers 2024). Pathway enrichment analyses revealed that targeted pathways, including WNT, NOTCH1, PI3K/AKT, MAPK, ERBB2, and FGFR signalling, form an interconnected oncogenic network. Within this framework, miR-378d and miR-449b-5p exhibited strong negative correlations with ERBB2 (-0.7 and -0.5, respectively). Consistent with these molecular interactions, Correlation with Scote-derived oncogenic signatures, including ERBB2 activation and BRCAness, demonstrated that miRNA clusters strongly associate with genomic instability, proliferation, and therapy resistance phenotypes. Collectively, these findings suggest that the identified miRNA clusters function as integrated regulatory modules that simultaneously coordinate the suppression of AR signalling crosstalk with PI3K/MAPK activation and modulation of EMT. Their strong associations with Scote oncogenic signatures and EMT transcription factors underscore their potential as prognostic biomarkers and as targets for rational combination strategies aimed at disrupting AR-survival network crosstalk and overcoming therapeutic resistance.
利益披露 Disclosure
F. Buono, None..
W. Lautert-Dutra, None..
D. Dion, None..
C. M. Melo, None..
C. Crozier, None..
F. P. Saggioro, None..
R. B. Reis, None..
J. A. Squire, None..
J. Bayani, None.